Evidence map›Paper›PMID 41319341›Full record

ArticleChemMedChem2026

Development of New Benzo[b]Thiophene-2-Carboxamide Derivatives as Advanced Glycation End-Products Receptor (RAGE) Antagonists.

Lisa Bonin, Matthieu Hedouin, Christophe Furman, Ophélie Not, Steve Lancel, Mona Bensalah, Gael Coadou, Eric Boulanger, Sergiu Shova, Hassan Oulyadi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lisa BoninJunia, Health and Environment, Laboratory of Sustainable Chemistry and Health, F-59000, Lille, France.
Matthieu HedouinUniv Rouen Normandie, INSA Rouen Normandie, CNRS, Normandie Univ, Institut CARMeN, UMR 6064, INC3M FR 3038, F-76000, Rouen, France.
Christophe FurmanUniv Lille, U1167-RID-AGE Risk Factors and molecular Determinants of Aging-Related Diseases, Inserm, CHU Lille, Institut Pasteur de Lille, F-59000, Lille, France.
Ophélie NotUniv Lille, U1167-RID-AGE Risk Factors and molecular Determinants of Aging-Related Diseases, Inserm, CHU Lille, Institut Pasteur de Lille, F-59000, Lille, France.
Steve LancelUniv Lille, U1167-RID-AGE Risk Factors and molecular Determinants of Aging-Related Diseases, Inserm, CHU Lille, Institut Pasteur de Lille, F-59000, Lille, France.
Mona BensalahMyoLine platform, Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, F-75013, Paris, France.
Gael CoadouUniv Rouen Normandie, INSA Rouen Normandie, CNRS, Normandie Univ, Institut CARMeN, UMR 6064, INC3M FR 3038, F-76000, Rouen, France.
Eric BoulangerUniv Lille, U1167-RID-AGE Risk Factors and molecular Determinants of Aging-Related Diseases, Inserm, CHU Lille, Institut Pasteur de Lille, F-59000, Lille, France.
Sergiu Shova'Petru Poni' Institute of Macromolecular Chemistry, Iasi, 700487, Romania.
Hassan OulyadiUniv Rouen Normandie, INSA Rouen Normandie, CNRS, Normandie Univ, Institut CARMeN, UMR 6064, INC3M FR 3038, F-76000, Rouen, France.
Alina GhinetJunia, Health and Environment, Laboratory of Sustainable Chemistry and Health, F-59000, Lille, France.ORCID https://orcid.org/0000-0001-6468-4331

Funding

Agence Nationale de la Recherche ANR-23-CE14-0063
6 · The paper itself

Abstract

The activation of the receptor for advanced glycation end-products (RAGE) induces a chronic, low-noise inflammation responsible for the aging process, known as inflammaging. Associated with numerous pathologies such as Alzheimer's, insulin-resistant diabetes, cardiovascular diseases, and certain cancers, RAGE has become an interesting therapeutic target in the context of aging well. To this end, we identified new benzo[b]thiophene-2-carboxamide derivatives as potential RAGE ligands. Herein, we developed an alternative approach to easily synthesize benzo[b]thiophene-2-carboxamide analogs from 5-arylidene-2,4-thiazolidinedione intermediates based on the Ullmann-Goldberg coupling conditions. In light of LCMS, NMR, X-ray, and DFT studies, a mechanism for this reaction was proposed. This novel strategy enabled us to synthesize analogs whose best molecule 3t', with an IC

Indexed as

Drug DevelopmentReceptor for Advanced Glycation End ProductsThiophenesDose-Response Relationship, DrugHumansLigandsMolecular StructureStructure-Activity RelationshipLigandsReceptor for Advanced Glycation End ProductsThiophenes5‐arylidene‐2,4‐thiazolidinedioneadvanced glycation end-product receptorantagonistbenzo[b]thiophene‐2‐carboxamidecopper

Identifiers

PMID41319341
PMCPMC12812012

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.